PNPLA3, the history of an orphan gene of the potato tuber protein family that found an organ: The liver
Silvia Sookoian, Carlos J. Pirola – 12 October 2013
The hunt for treatment options of fatty liver continues: Effects of retinoic acid on hepatic steatosis reveal novel transcriptional interactions of nuclear receptors
Lars P. Bechmann, Ali Canbay – 12 October 2013
A new role for IKK‐α in hepatitis C virus‐induced lipogenesis
Mark W. Douglas, Saeed Esmaili, Jacob George – 9 October 2013
Serum bile acids in intrahepatic cholestasis of pregnancy: Not just a diagnostic test
Laura N. Bull, Juan Vargas – 9 October 2013
Reply
Brian L. Pearlman, Carole M. Ehleben – 9 October 2013
Antitumor CD8+T cells in hepatocellular carcinoma: Present but exhausted
Ka‐Kit Li, David H. Adams – 9 October 2013
The road not taken or how I learned to love the liver: A personal perspective on hepatitis history
Harvey J. Alter – 9 October 2013
Drug‐induced removal of nitrogen derivatives in urine: A new concept whose time has come
Juan Córdoba, Meritxell Ventura‐Cots – 9 October 2013
Small proline rich protein 2a in benign and malignant liver disease
Yoshiaki Mizuguchi, Kumiko Isse, Susan Specht, John G. Lunz, Natasha Corbitt, Toshihiro Takizawa, Anthony J. Demetris – 9 October 2013 – STAT3‐driven expression of small proline rich protein 2a (SPRR2a), which acts as an src homology 3 (SH3) domain ligand, induces biliary epithelial cell (BEC) epithelial‐mesenchymal transition (EMT), which, in turn, promotes wound healing. SPRR2a also quenches free radicals and protects against oxidative stress and DNA damage in nonneoplastic BEC. Sprr2a‐induced EMT also increases local invasiveness of cholangiocarcinomas (CC), but prevents metastases.
How sweet it is to activate FXR
Peter L.M. Jansen, Frank G. Schaap – 9 October 2013